drugset / Trial / NCT05761444

Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients

NCT05761444

Phase 4 Completed 137 enrolled Organon and Co IQVIA Pty Ltd · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to confirm the effectiveness of ezetimibe add-on therapy on LDL-C levels compared to atorvastatin monotherapy, especially in very high-risk patients. We intend to lay the foundation for a standard treatment for these patients through ezetimibe add on lipid-lowering therapy.

Timeline

Start
2023-07-26
Primary completion
2024-09-04
Completion
2024-10-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 40 mg Oral
Comparator Atorvastatin Small molecule 80 mg Oral
Subject Ezetimibe Unknown 10 mg Oral